NCT05903794View on ClinicalTrials.gov

A Study of EXG102-031 in Patients With wAMD (Everest)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Interventions
BIOLOGICAL

EXG102-031

EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein. EXG102-031 will be administered by subretinal injecting into one eye of each participant.

Trial Locations (2)

16507

Erie Retina Research, Erie

89502

Sierra Eye Associates, Reno

Sponsors

Lead Sponsor

Exegenesis Bio
All Listed Sponsors
lead

Exegenesis Bio

INDUSTRY

NCT05903794 - A Study of EXG102-031 in Patients With wAMD (Everest) | Biotech Hunter | Biotech Hunter